Edition:
United Kingdom

Grifols SA (GRLSbn.MC)

GRLSbn.MC on Madrid SE C.A.T.S.

16.82EUR
22 Feb 2019
Change (% chg)

€-0.06 (-0.36%)
Prev Close
€16.88
Open
€17.58
Day's High
€17.58
Day's Low
€16.72
Volume
78,167
Avg. Vol
139,116
52-wk High
€21.30
52-wk Low
€15.60

Latest Key Developments (Source: Significant Developments)

Grifols Receives FDA Approval For Procleix Babesia Assay For Donor Screening On Procleix Panther System
Thursday, 7 Feb 2019 

Feb 7 (Reuters) - Grifols SA ::GRIFOLS RECEIVES FDA APPROVAL FOR PROCLEIX BABESIA ASSAY FOR DONOR SCREENING ON PROCLEIX PANTHER SYSTEM.  Full Article

Grifols Starts Talks To Invest In Shanghai RAAS Blood Products
Wednesday, 21 Nov 2018 

Nov 21 (Reuters) - Grifols ::SAYS STARTED TALKS WITH SHANGHAI RAAS BLOOD PRODUCTS TO MAKE INVESTMENT IN THIS COMPANY LISTED IN SHENZHEN STOCK EXCHANGE.TO INVEST IN CO THROUGH GRIFOLS DIAGNOSTIC SOLUTIONS INC AND ITS SUBSIDIARIES, RECEIVING IN EXCHANGE SHANGHAI RAAS NEWLY ISSUED SHARES.SAYS VALUATION OF 100 PERCENT SHARES OF GRIFOLS DIAGNOSTIC SOLUTIONS IS ABOUT $5 BILLION.  Full Article

Grifols Approves Interim Dividend Of 0.20 Eur/Shr
Friday, 2 Nov 2018 

Nov 2 (Reuters) - Grifols SA ::SAYS APPROVES INTERIM DIVIDEND OF 0.20 EURO PER SHARE TO BE PAID ON DEC. 4.  Full Article

Grifols Says AMBAR Results Show Reduction In Progression of Moderate Alzheimer's Disease
Saturday, 27 Oct 2018 

Oct 29 (Reuters) - Grifols SA ::SAID ON SATURDAY THAT AMBAR CLINICAL TRIAL DEMONSTRATED THE ABILITY TO SLOW DOWN THE PROGRESSION OF THE DISEASE IN MODERATE ALZHEIMER'S DISEASE (AD) PATIENTS.THE RESULTS IN THE PRESPECIFIED COHORT OF THE PATIENTS SHOWED A REDUCTION OF 61% IN DISEASE PROGRESSION IN BOTH PRIMARY EFFICACY ENDPOINTS MEASURING COGNITION AND ACTIVITIES OF DAILY LIVING DURING A 14 MONTH PERIOD .AMBAR (ALZHEIMER MANAGEMENT BY ALBUMIN REPLACEMENT) AIMS TO EVALUATE WHETHER AD CAN BE STABILIZED BY PERIODICALLY EXTRACTING PLASMA AND REPLACING IT WITH ALBUMIN .  Full Article

Grifols Reaches 25 Pct In Mecwins With Investment Of 2 Mln Euros
Monday, 22 Oct 2018 

Oct 22 (Reuters) - Grifols SA ::SAYS VIA UNIT SUBSCRIBES FOR MECWINS' SHARES FOR 2 MILLION EUROS REACHING 25 PERCENT IN THE CO.MECWINS FOCUSES ON DEVELOPMENT OF ULTRASENSITIVE IMMUNOASSAYS FOR DETECTION OF PROTEIN BIOMARKERS.  Full Article

Grifols Disagrees With UBS Report On Potential Impact Of FcRn Inhibitors
Wednesday, 3 Oct 2018 

Oct 3 (Reuters) - Grifols SA ::SAYS DISAGREES WITH UBS REPORT CONCLUSIONS IN RELATION TO POTENTIAL IMPACT OF FCRN INHIBITORS ON CO'S IMMUNOGLOBULIN BUSINESS.SAYS REPORT IS BASED SOLELY ON PRELIMINARY CLINICAL STUDIES WITH LIMITED NUMBER OF PATIENTS, THUS RESULTS ARE NOT CONCLUSIVE.  Full Article

Grifols Says FDA Approves New Gamastan To Treat Patients Exposed To Hepatitis A And Measles
Tuesday, 4 Sep 2018 

Sept 4 (Reuters) - Grifols SA ::FDA APPROVES A NEW FORMULATION OF GAMASTAN (IMMUNOGLOBULIN) TO TREAT PATIENTS EXPOSED TO HEPATITIS A AND MEASLES.GAMASTAN IS THE ONLY IMMUNOGLOBULIN APPROVED IN THE US MARKET FOR IMMEDIATE PROTECTION AGAINST HEPATITIS A AND MEASLES VIRUSES.  Full Article

Grifols H1 EBITDA Down 4.7 Pct At 614.2 Mln Euros YoY
Friday, 27 Jul 2018 

July 27 (Reuters) - Grifols SA ::H1 EBITDA 614.2 MILLION EUROS VERSUS 644.4 MILLION EUROS YEAR AGO.H1 NET REVENUE 2.12 BILLION EUROS VERSUS 2.19 BILLION EUROS YEAR AGO.H1 NET PROFIT 319.0 MILLION EUROS VERSUS 277.9 MILLION EUROS YEAR AGO.H1 RESEARCH AND DEVELOPMENT NET INVESTMENT 141.3 MILLION EUROS VERSUS 129.3 MILLION EUROS YEAR AGO.H1 ADJUSTED NET PROFIT 355.9 MILLION EUROS VERSUS 330.2 MILLION EUROS YEAR AGO.FINANCIAL RESULTS AND LOWER TAXES IN THE U.S. CONTRIBUTE TO A 15% INCREASE IN NET PROFIT.  Full Article

Grifols To Pay Gross Dividend Of 0.204 Euro per Share
Friday, 25 May 2018 

May 25 (Reuters) - Grifols SA ::TO PAY GROSS DIVIDEND OF 0.204 EUR PER SHARE AGAINST FY 2017.  Full Article

Grifols says FDA approves genetic test and EMA biological sealant
Friday, 17 Nov 2017 

Nov 17 (Reuters) - GRIFOLS SA ::GETS APPROVAL FROM US FOOD AND DRUG ADMINISTRATION (FDA) FOR ITS NEW GENETIC TEST TO DETECT ALPHA-1 ANTITRYPSIN DEFICIENCY‍​.THE EUROPEAN MEDICINES AGENCY (EMA) APPROVES NEW PRODUCT, BIOLOGICAL SEALANT, TO USE IN SURGICAL OPERATIONS IN ADULTS.‍​.  Full Article

Grifols SA News

Spanish stocks - Factors to watch on Friday

The following Spanish stocks may be affected by newspaper reports and other factors on Friday. Reuters has not verified the newspaper reports, and cannot vouch for their accuracy:

» More GRLSbn.MC News

Earnings vs. Estimates

» More Financials